Boan Biotech Announces 2025 Half-Year Results

Boan Biotech (6955.HK) today announced its 2025 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 393 million, up 8% YoY, and the contribut...

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025

NOTICE OF BOARD MEETING

Next Day Disclosure Return

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing

Yantai, August 8, 2025 –- Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping® (Dulaglutide Injection), indi...

VOLUNTARY ANNOUNCEMENT DULAGLUTIDE INJECTION (BOYOUPING) APPROVED FOR MARKETING IN CHINA

PLACING OF NEW SHARES UNDER GENERAL MANDATE

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025

Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert

Recently, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), as a standing observer of the International Council for Harmonisation of Technical Requirements for P...